Search hospitals
>
Texas
>
Houston
Houston Methodist Hospital
Claim this profile
Houston, Texas 77030
Global Leader in Stroke
Global Leader in Breast Cancer
Conducts research for Lung Cancer
Conducts research for Heart Failure
Conducts research for Mixed-Cell Lymphoma
821 reported clinical trials
101 medical researchers
Summary
Houston Methodist Hospital is a medical facility located in Houston, Texas. This center is recognized for care of Stroke, Breast Cancer, Lung Cancer, Heart Failure, Mixed-Cell Lymphoma and other specialties. Houston Methodist Hospital is involved with conducting 821 clinical trials across 1,021 conditions. There are 101 research doctors associated with this hospital, such as Jun Zhang, Carlos Ramos, MD, Maen Abdelrahim, MD, and Rayne H. Rouce.
Area of expertise
Stroke
Houston Methodist Hospital has run 44 trials for Stroke.
Breast Cancer
Houston Methodist Hospital has run 44 trials for Breast Cancer. Some of their research focus areas include:
Top PIs
Jun Zhang
Houston Methodist Hospital
5 years of reported clinical research
Carlos Ramos, MD
Houston Methodist Hospital
3 years of reported clinical research
Maen Abdelrahim, MD
Houston Methodist
2 years of reported clinical research
Rayne H. Rouce
Texas Children's Hospital
6 years of reported clinical research
Clinical Trials running at Houston Methodist Hospital
Lung Cancer
Ovarian Cancer
Prostate Cancer
Multiple Myeloma
Breast Cancer
Bladder Cancer
Uterine Cancer
Pancreatic Cancer
Fallopian Tube Cancer
Non-Small Cell Lung Cancer
Crizotinib
for Non-Small Cell Lung Cancer
This randomized phase III trial studies how well crizotinib works in treating patients with stage IB-IIIA non-small cell lung cancer that has been removed by surgery and has a mutation in a protein called anaplastic lymphoma kinase (ALK). Mutations, or changes, in ALK can make it very active and important for tumor cell growth and progression. Crizotinib may stop the growth of tumor cells by blocking the ALK protein from working. Crizotinib may be an effective treatment for patients with non-small cell lung cancer and an ALK fusion mutation.
Recruiting
2 awards
Phase 3
28 criteria
Osimertinib + Bevacizumab
for Lung Cancer
This phase III trial compares the effect of bevacizumab and osimertinib combination vs. osimertinib alone for the treatment of non-small cell lung cancer that has spread outside of the lungs (stage IIIB-IV) and has a change (mutation) in a gene called EGFR. The EGFR protein is involved in cell signaling pathways that control cell division and survival. Sometimes, mutations in the EGFR gene cause EGFR proteins to be made in higher than normal amounts on some types of cancer cells. This causes cancer cells to divide more rapidly. Osimertinib may stop the growth of tumor cells by blocking EGFR that is needed for cell growth in this type of cancer. Bevacizumab is in a class of medications called antiangiogenic agents. It works by stopping the formation of blood vessels that bring oxygen and nutrients to tumor. This may slow the growth and spread of tumor. Giving osimertinib with bevacizumab may control cancer for longer and help patients live longer as compared to osimertinib alone.
Recruiting
2 awards
Phase 3
31 criteria
Immunotherapy + Chemotherapy
for Non-Small Cell Lung Cancer
This phase III ALCHEMIST treatment trial tests the addition of pembrolizumab to usual chemotherapy for the treatment of stage IIA, IIB, IIIA or IIIB non-small cell lung cancer that has been removed by surgery. Immunotherapy with monoclonal antibodies, such as pembrolizumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Chemotherapy drugs, such as cisplatin, pemetrexed, carboplatin, gemcitabine hydrochloride, and paclitaxel, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Giving pembrolizumab with usual chemotherapy may help increase survival times in patients with stage IIA, IIB, IIIA or IIIB non-small cell lung cancer.
Recruiting
2 awards
Phase 3
27 criteria
Similar Hospitals nearby
Select from list below to view details
Frequently asked questions
What kind of research happens at Houston Methodist Hospital?
Houston Methodist Hospital is a medical facility located in Houston, Texas. This center is recognized for care of Stroke, Breast Cancer, Lung Cancer, Heart Failure, Mixed-Cell Lymphoma and other specialties. Houston Methodist Hospital is involved with conducting 821 clinical trials across 1,021 conditions. There are 101 research doctors associated with this hospital, such as Jun Zhang, Carlos Ramos, MD, Maen Abdelrahim, MD, and Rayne H. Rouce.
Where is Houston Methodist Hospital located?
Houston Methodist Hospital's main campus is situated at 6565 Fannin Street, within the Texas Medical Center in Houston, Texas. For access, take I-69/US-59 South towards downtown Houston, exit at Fannin Street, turn right, and proceed for about 1 mile. The hospital will be on your left.
Who should I call to ask about financial aid or insurance network?
Houston Methodist Hospital provides financial assistance for uninsured or underinsured patients unable to afford medically necessary care, including emergency services. For details on their financial assistance policy or to apply, contact the hospital at (713) 790-3311 or visit their website. Ensure you have your ID card, insurance card, and driver's license when visiting Admitting/Registration.
What insurance does Houston Methodist Hospital accept?
Houston Methodist Hospital accepts a wide range of insurance plans, including EPO, HMO, Indemnity, Medicare HMO & PPO, POS, PPO, Premier Care Network, and Premier Care Network Plus Multi-Tier. It is in-network with several insurance providers such as Aetna, Blue Cross and Blue Shield of Texas, Cigna, Humana, and United Healthcare, among others. To determine individual coverage, patients are advised to contact their insurance carrier directly.
What awards or recognition has Houston Methodist Hospital received?
Houston Methodist Hospital, located in Houston, Texas, has been named the Best Hospital in Texas for 12 consecutive years by U.S. News & World Report. It boasts national rankings in 10 specialties and high-performing scores in 18 out of 21 common conditions and procedures. The hospital is also celebrated for its innovative contributions to healthcare, including FDA clearance for a novel craniomaxillofacial surgery software and significant research achievements in treating glioblastomas, earning the 2022 Houston Inno Fire Award for innovation in health care and life sciences.
Unbiased Results
We believe in providing patients with all the options.
Your Data Stays Your Data
We only share your information with the clinical trials you're trying to access.
Verified Trials Only
All of our trials are run by licensed doctors, researchers, and healthcare companies.
Unbiased Results
We believe in providing patients with all the options.
Your Data Stays Your Data
We only share your information with the clinical trials you're trying to access.
Verified Trials Only
All of our trials are run by licensed doctors, researchers, and healthcare companies.